Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 12/2014

01-12-2014 | ALLERGENS (RK BUSH AND JA WOODFOLK, SECTION EDITORS)

Modified Allergens and their Potential to Treat Allergic Disease

Authors: Laurian Jongejan, Ronald van Ree

Published in: Current Allergy and Asthma Reports | Issue 12/2014

Login to get access

Abstract

Allergen-specific immunotherapy is the only treatment of allergic diseases that aims at modifying the underlying immune mechanism. Current protocols are long and at risk of anaphylactic reactions. The main aim of current research is decreasing the risk of side effects and increasing efficacy, in particular targeting reduction of treatment duration. Since the advent of molecular biology, extracts can be replaced by recombinant hypo-allergens, peptides, or fusion proteins. In addition, different routes of administration are being pursued as well as the addition of new adjuvants that are targeted at skewing the immune system away from a Th2 to a more Th1 or regulatory T cell phenotype. In this review, we summarize the recent advances in this field focusing on the allergen modifications and new adjuvants.
Literature
1.
Larenas-Linnemann D, Pfaar O. Patient-reported outcomes and quality-of-life questionnaires in the assessment of rhinoconjunctivitis in childhood. Curr Opin Allergy Clin Immunol. 2014;14:192–9.PubMed
2.
Zuberbier T, Lotvall J, Simoens S et al.: Economic burden of inadequate management of allergic diseases in the european union: a galen review. Allergy. 2014; in press.
3.
Bjorksten B, Clayton T, Ellwood P, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the international study of asthma and allergies in childhood. Pediatr Allergy Immunol. 2008;19:110–24.PubMedCrossRef
4.
5.
Kudzyte J, Griska E, Bojarskas J. Time trends in the prevalence of asthma and allergy among 6-7-year-old children. Results from Isaac phase I and III studies in Kaunas, Lithuania. Med Kaunas Lith. 2008;44:944–52.
6.
Liao MF, Liao MN, Lin SN, et al. Prevalence of allergic diseases of schoolchildren in central Taiwan. From Isaac surveys 5 years apart. J asthma Off J Assoc Care Asthma. 2009;46:541–5.CrossRef
7.
Nwaru BI, Hickstein L, Panesar SS, et al. The epidemiology of food allergy in Europe: a systematic review and meta-analysis. Allergy. 2014;69:62–75.PubMedCrossRef
8.
Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007;120:638–46.PubMedCrossRef
9.
Zuidmeer L, Goldhahn K, Rona RJ, et al. The prevalence of plant food allergies: a systematic review. J Allergy Clin Immunol. 2008;121:1210–8.PubMedCrossRef
10.
Sicherer SH, Munoz-Furlong A, Godbold JH, et al. Us prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol. 2010;125:122–6.
11.
Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med. 1999;189:1885–94.PubMedCentralPubMedCrossRef
12.
Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468–75.PubMedCrossRef
13.•
Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014;133:621–31. Review on the mechanisms of allergy immunotherapy.PubMedCrossRef
14.••
van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131:1204–12. This paper shows the interesting finding that not only T-regulatory cells play a role in succes of SIT, but human IL-10–secreting BR1 cells potently suppress antigen-specific T-cell responses.PubMedCrossRef
15.
Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American academy of allergy, asthma and immunology/European academy of allergy and clinical immunology/practall consensus report. J Allergy Clin Immunol. 2013;131:1288–96.PubMedCrossRef
16.
Mackenzie KJ, Fitch PM, Leech MD, et al. Combination peptide immunotherapy based on t-cell epitope mapping reduces allergen-specific IgE and eosinophilia in allergic airway inflammation. Immunology. 2013;138:258–68.PubMedCentralPubMedCrossRef
17.
Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;177:1572–3.CrossRef
18.••
Marth K, Focke-Tejkl M, Lupinek C, et al. Allergen peptides, recombinant allergens and hypoallergens for allergen-specific immunotherapy. Curr Treat Options Allergy. 2014;1:91–106. This study thoroughly reviews the newest developments in the area of (modified) recombinant allergens. PubMedCentralPubMedCrossRef
19.
Ring J, Gutermuth J. 100 years of hyposensitization: history of allergen-specific immunotherapy (asit). Allergy. 2011;66:713–24.PubMedCrossRef
20.
Kiel MA, Roder E, van Wijk GR, et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013;132:353–60. e352.PubMedCrossRef
21.
Passalacqua G, Canonica GW. Local nasal specific immunotherapy for allergic rhinitis. Allergy Asthma Clin Immunol Off J Can Soc Allergy Clin Immunol. 2006;2:117–23.CrossRef
22.
Passalacqua G, Albano M, Pronzato C, et al. Long-term follow-up of nasal immunotherapy to parietaria: clinical and local immunological effects. Clin Exp Allergy. 1997;27:904–8.PubMedCrossRef
23.
Andri L, Falagiani P. Symptomatic relief after grass nasal immunotherapy: lasting efficacy after 4–5 years. J Investig Allergol Clin Immunol. 2003;13:228–31.PubMed
24.
Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129:1290–6.PubMedCrossRef
25.
Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105:17908–12.PubMedCentralPubMedCrossRef
26.
Johansen P, von Moos S, Mohanan D, et al. New routes for allergen immunotherapy. Hum Vaccines Immunother. 2012;8:1525–33.CrossRef
27.••
Witten M, Malling HJ, Blom L, et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013;132:1248–52. Challenges the promising results described with ILIT so far, in their study with grasspollen ILIT showing no improvement. PubMedCrossRef
28.
Kundig TM, Johansen P, Bachmann MF, et al. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014;133:930–1.PubMedCrossRef
29.
Malling HJ, Witten M, Poulsen LK. Reply: to pmid 24035151. J Allergy Clin Immunol. 2014;133:931–2.PubMedCrossRef
30.
31.
Rotiroti G, Shamji M, Durham SR, et al. Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol. 2012;130:918–24. e911.PubMedCrossRef
32.
Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124:997–1002.PubMedCrossRef
33.
Senti G, Johansen P, Martinez GJ, et al. Efficacy and safety of allergen-specific immunotherapy in rhinitis, rhinoconjunctivitis, and bee/wasp venom allergies. Int Rev Immunol. 2005;24:519–31.PubMedCrossRef
34.
Nelson HS, Lahr J, Rule R, et al. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99:744–51.PubMedCrossRef
35.
Oppenheimer JJ, Nelson HS, Bock SA, et al. Treatment of peanut allergy with rush immunotherapy. J Allergy Clin Immunol. 1992;90:256–62.PubMedCrossRef
36.••
Jones SM, Burks AW, Dupont C. State of the art on food allergen immunotherapy: oral, sublingual, and epicutaneous. J Allergy Clin Immunol. 2014;133:318–23. This study gives an excellent overview of current treatment options in food allergy. PubMedCrossRef
37.
38.•
Fleischer DM, Burks AW, Vickery BP, et al. Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial. J Allergy Clin Immunol. 2013;131:119–27. This paper describes a first step towards a treatment of peanut allergy.PubMedCentralPubMedCrossRef
39.
Dupont C, Kalach N, Soulaines P, et al. Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity. J Allergy Clin Immunol. 2010;125:1165–7.PubMedCrossRef
40.
Agbotounou W, Martin L, Dupont B, et al. Epicutaneous immunotherapy (epit) is safe for the treatment of peanut allergy in allergic patients. J Allergy Clin Immunol. 2013;131:AB91.CrossRef
41.•
Dupont C, Bourrier T, de Blay F, et al. Peanut epicutaneous immunotherapy (epit) in peanut-allergic children: 18 months treatment in the arachild study. J Allergy Clin Immunol. 2014;133:AB102. First tentative positive response with peanut EPIT described. CrossRef
42.
Wood RA, Sicherer SH, Burks AW, et al. A phase 1 study of heat/phenol-killed, E. coli-encapsulated, recombinant modified peanut proteins ara h 1, ara h 2, and ara h 3 (emp-123) for the treatment of peanut allergy. Allergy. 2013;68:803–8.PubMedCentralPubMedCrossRef
43.
Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol. 2002;2:446–53.PubMed
44.
Focke-Tejkl M, Valenta R. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol. 2012;12:555–63.PubMedCrossRef
45.
Swoboda I, Bugajska-Schretter A, Linhart B, et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol. 2007;178:6290–6.PubMedCrossRef
46.
Zuidmeer-Jongejan L, Fernandez-Rivas M, Poulsen LK, et al. Fast: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies. Clin Transl Allergy. 2012;2:5.PubMedCentralPubMedCrossRef
47.
Niemi M, Janis J, Jylha S, et al. Characterization and crystallization of a recombinant IgE fab fragment in complex with the bovine beta-lactoglobulin allergen. Acta Crystallogr Sect F: Struct Biol Cryst Commun. 2008;64:25–8.CrossRef
48.
Haselden BM, Larche M, Meng Q, et al. Late asthmatic reactions provoked by intradermal injection of t-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or t(h)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J Allergy Clin Immunol. 2001;108:394–401.PubMedCrossRef
49.•
Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103–9. DBPC trial in over 200 patients showing that a short-course (4 administrations) immunotherapy with T-cell epitopes significantly improves clinical symptoms of cat allergen–induced rhinoconjunctivitis 1 year after the start of treatment.PubMedCrossRef
50.
Worm M, Patel D, Creticos PS. Cat peptide antigen desensitisation for treating cat allergic rhinoconjunctivitis. Exp Opin Investig Drugs. 2013;22:1347–57.CrossRef
51.
Niespodziana K, Focke-Tejkl M, Linhart B, et al. A hypoallergenic cat vaccine based on fel d 1-derived peptides fused to hepatitis b preS. J Allergy Clin Immunol. 2011;127:1562–70.PubMedCrossRef
52.
Fellrath JM, Kettner A, Dufour N, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol. 2003;111:854–61.PubMedCrossRef
53.
Pellaton C, Perrin Y, Boudousquie C, et al. Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Trans Allergy. 2013;3:17.CrossRef
54.
Pfaar O, Cazan D, Klimek L, et al. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol. 2012;12:648–57.PubMedCrossRef
55.
De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol. 2008;38:2068–71.PubMedCrossRef
56.
Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2009;103:451–9.CrossRef
57.
Kramer MF, Heath MD. Aluminium in allergen-specific subcutaneous immunotherapy—a German perspective. Vaccine. 2014;32:4140–8.PubMedCrossRef
58.•
De Souza RJ, Esparza I, Ferrer M, et al. Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol. 2012;2012:474605. Nice review on various delivery systems for immunotherapy.
59.
Gupta PN, Mishra V, Rawat A, et al. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study. Int J Pharm. 2005;293:73–82.PubMedCrossRef
60.
Matsuo K, Hirobe S, Okada N, et al. Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery. Vaccine. 2013;31:2403–15.PubMedCrossRef
61.•
Kawakita A, Shirasaki H, Yasutomi M, et al. Immunotherapy with oligomannose-coated liposomes ameliorates allergic symptoms in a murine food allergy model. Allergy. 2012;67:371–9. Promising in vitro data with coated liposomes to treat food allergy.PubMedCrossRef
62.
Busse W, Gross G, Korenblat P, et al. Phase 2/3 study of the novel vaccine amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate AIC in ragweed-allergic adults. J Allergy Clin Immunol. 2006;117(2):S88–S89.
63.
Senti G, Johansen P, Haug S, et al. Use of a-type cpg oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39:562–70.PubMedCrossRef
64.
DuBuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32:239–47.PubMedCrossRef
65.
Beeh KM, Kanniess F, Wagner F, et al. The novel tlr-9 agonist qbg10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol. 2013;131:866–74.PubMedCrossRef
66.
Roy K, Mao HQ, Huang SK, et al. Oral gene delivery with chitosan–DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5:387–91.PubMedCrossRef
67.
Tourdot S, Airouche S, Berjont N, et al. Efficacy of sublingual vectorized recombinant bet v 1a in a mouse model of birch pollen allergic asthma. Vaccine. 2013;31:2628–37.PubMedCrossRef
68.
69.
Reinholz M, Ruzicka T, Schauber J. Vitamin d and its role in allergic disease. Clin Exp Allergy. 2012;42:817–26.PubMed
70.
Taher YA, van Esch BC, Hofman GA, et al. 1alpha,25-dihydroxyvitamin d3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for il-10 and tgf-beta. J Immunol. 2008;180:5211–21.PubMedCrossRef
71.•
Heine G, Tabeling C, Hartmann B, et al. 25-hydroxvitamin d3 promotes the long-term effect of specific immunotherapy in a murine allergy model. J Immunol. 2014;193:1017–23. This paper (together with refs 74 and 75) show vitamin D may be an interesting candidate to include in new allergy vaccines.PubMedCrossRef
72.
Baris S, Kiykim A, Ozen A, et al. Vitamin d as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite. Allergy. 2014;69:246–53.PubMedCrossRef
73.
van der Aar AM, Sibiryak DS, Bakdash G, et al. Vitamin d3 targets epidermal and dermal dendritic cells for induction of distinct regulatory t cells. J Allergy Clin Immunol. 2011;127:1532–40. e1537.PubMedCrossRef
74.•
Bakdash G, Schneider LP, van Capel TM, et al. Intradermal application of vitamin d3 increases migration of cd14+ dermal dendritic cells and promotes the development of foxp3+ regulatory t cells. Hum Vaccines Immunother. 2013;9:250–8. This study indicated vitamin D3 promotes DC migration and stimulate the development of regulatory T-cells. CrossRef
75.•
Grundstrom J, Neimert-Andersson T, Kemi C, et al. Covalent coupling of vitamin d3 to the major cat allergen fel d 1 improves the effects of allergen-specific immunotherapy in a mouse model for cat allergy. Int Arch Allergy Immunol. 2012;157:136–46. Together with refs 71 and 74 this study indicates vitamin D3 might be considered a promising adjuavant. PubMedCrossRef
Metadata
Title
Modified Allergens and their Potential to Treat Allergic Disease
Authors
Laurian Jongejan
Ronald van Ree
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 12/2014
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-014-0478-9

Other articles of this Issue 12/2014

Current Allergy and Asthma Reports 12/2014 Go to the issue

IMMUNOTHERAPY AND IMMUNOMODULATORS (L COX, SECTION EDITOR)

Immunotherapy for House Dust Mite Sensitivity: Where Are the Knowledge Gaps?

Immune Deficiency and Dysregulation (DP Huston, Section Editor)

Common Dermatologic Manifestations of Primary Immune Deficiencies

ASTHMA (WJ CALHOUN AND SP PETERS, SECTION EDITORS)

Emerging Issues in Pediatric Asthma: Gaps in EPR-3 Guidelines for Infants and Children

RHINOSINUSITIS (J MULLOL, SECTION EDITOR)

The Nasal and Sinus Microbiome in Health and Disease

ASTHMA (WJ CALHOUN AND SP PETERS, SECTION EDITORS)

Anticholinergics/Antimuscarinic Drugs in Asthma

Immune Deficiency and Dysregulation (DP Huston, Section Editor)

The Expanding Spectrum of Human coronin 1A deficiency